Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation
- PMID: 30554355
- DOI: 10.1007/s10072-018-3685-7
Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation
Abstract
Objective: The hexanucleotide repeat expansion in C9orf72 is an associated genetic cause in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In the "ALS/FTD" spectrum prevails clinical heterogeneity and an in vivo knowledge of the underling brain dysfunction in patients carrying C9orf72 mutation remain limited and only described at group level. The study aimed to assess the brain metabolic alterations characterizing patients with C9orf72 mutation using FDG-PET in single individuals.
Methods: We applied a validated statistical parametric mapping (SPM) voxel-based procedure for FDG-PET data to obtain maps of brain relative hypometabolism and hypermetabolism at single-subject level in six FTD/ALS patients carrying the C9orf72 mutation.
Results: Clinical diagnoses classified the patients as right semantic variant of frontotemporal dementia (one case, C9svFTD), behavioral variant of frontotemporal dementia (two cases, C9bvFTD), and bulbar amyotrophic lateral sclerosis (three cases, C9bALS). The FDG-PET SPM revealed a prevalent frontal hypometabolism in C9bvFTD cases, and right temporal polar and lateral involvement in C9svFTD, consistent with the clinical diagnosis. There was a quite comparable occipital and cerebellar hypermetabolism in these cases. The three C9bALS patients showed variable patterns of hypo- and hypermetabolism.
Conclusions: The present work is the first in vivo FDG-PET study showing the heterogeneous patterns of brain regional hypo- and hypermetabolism in single patients sharing C9orf72 mutation. Brain hypometabolism was consistent with the clinical phenotypes, supporting the diagnostic importance of neuroimaging functional biomarkers to capture at single-subject level specific brain dysfunction.
Keywords: ALS-FTD spectrum; C9orf72; Heterogeneity; Positron emission tomography; Statistical parametric mapping.
Similar articles
-
Clinical relevance of single-subject brain metabolism patterns in amyotrophic lateral sclerosis mutation carriers.Neuroimage Clin. 2022;36:103222. doi: 10.1016/j.nicl.2022.103222. Epub 2022 Oct 5. Neuroimage Clin. 2022. PMID: 36223668 Free PMC article.
-
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients.Eur J Nucl Med Mol Imaging. 2014 May;41(5):844-52. doi: 10.1007/s00259-013-2667-5. Epub 2014 Jan 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 24445987 Free PMC article.
-
Brain ¹⁸F-FDG and ¹¹C-PiB PET findings in two siblings with FTD/ALS associated with the C9ORF72 repeat expansion.Neurocase. 2014 Apr;20(2):150-7. doi: 10.1080/13554794.2012.741252. Epub 2012 Dec 5. Neurocase. 2014. PMID: 23216213
-
Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum.J Med Genet. 2017 Mar;54(3):145-154. doi: 10.1136/jmedgenet-2016-104271. Epub 2017 Jan 13. J Med Genet. 2017. PMID: 28087719 Review.
-
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.Mol Neurodegener. 2020 Jun 8;15(1):34. doi: 10.1186/s13024-020-00383-7. Mol Neurodegener. 2020. PMID: 32513219 Free PMC article. Review.
Cited by
-
Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects.Front Neurol. 2022 Aug 16;13:933217. doi: 10.3389/fneur.2022.933217. eCollection 2022. Front Neurol. 2022. PMID: 36051222 Free PMC article. Review.
-
Metabolic Alteration and Amyotrophic Lateral Sclerosis Outcome: A Systematic Review.Front Neurol. 2019 Nov 20;10:1205. doi: 10.3389/fneur.2019.01205. eCollection 2019. Front Neurol. 2019. PMID: 31824397 Free PMC article.
-
PET and SPECT Imaging of ALS: An Educational Review.Mol Imaging. 2023 Aug 19;2023:5864391. doi: 10.1155/2023/5864391. eCollection 2023. Mol Imaging. 2023. PMID: 37636591 Free PMC article. Review.
-
The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.Brain Imaging Behav. 2021 Oct;15(5):2693-2719. doi: 10.1007/s11682-020-00429-w. Epub 2021 Jan 5. Brain Imaging Behav. 2021. PMID: 33398779
-
ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population.Neurol Sci. 2019 Jun;40(6):1237-1244. doi: 10.1007/s10072-019-03825-3. Epub 2019 Mar 16. Neurol Sci. 2019. PMID: 30879219
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous